Evidence map›Paper›PMID 40980470›Full record

ArticleRisk management and healthcare policy2025

Optimized Homologous Sequence Alignment for the Identification of CYP21A2 Variants in 21-Hydroxylase Deficiency Using Next-Generation Sequencing Technology.

Yibo Chen, Qi Yu, Lisha Ge, Lixin Weng, Xiaoli Pan, Xiaoxia Zhou, Nani Zhou, Yanjie Wang, Jia Jia, Haibo Li

Abstract read
In one paragraph

Article in Risk management and healthcare policy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yibo ChenDepartment of Clinical Laboratory, Women and Children's Hospital of Ningbo University, Ningbo, 315012, People's Republic of China.
Qi YuNeonatal Screening Center, Women and Children's Hospital of Ningbo University, Ningbo, 315012, People's Republic of China.
Lisha GeThe Central Laboratory of Birth Defects Prevention and Control, Women and Children's Hospital of Ningbo University, Ningbo, 315012, People's Republic of China.
Lixin WengDepartment of Clinical Laboratory, Ningbo Yinzhou District Maternity and Child Healthcare Hospital, Ningbo, 315000, People's Republic of China.
Xiaoli PanThe Central Laboratory of Birth Defects Prevention and Control, Women and Children's Hospital of Ningbo University, Ningbo, 315012, People's Republic of China.
Xiaoxia ZhouShanghai Fujungenetics Biotechnology Co., Ltd, Shanghai, 201900, People's Republic of China.
Nani ZhouShanghai Fujungenetics Biotechnology Co., Ltd, Shanghai, 201900, People's Republic of China.
Yanjie WangShanghai Fujungenetics Biotechnology Co., Ltd, Shanghai, 201900, People's Republic of China.
Jia JiaShanghai Fujungenetics Biotechnology Co., Ltd, Shanghai, 201900, People's Republic of China.
Haibo LiThe Central Laboratory of Birth Defects Prevention and Control, Women and Children's Hospital of Ningbo University, Ningbo, 315012, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: This study aimed to develop a novel homologous sequence analysis technique using high-throughput sequencing data to enhance CYP21A2 mutation detection. The approach leverages next-generation sequencing to overcome existing limitations and improve 21-hydroxylase deficiency diagnostic accuracy. Methods: From April 21, 2022, to February 21, 2023, a total of 100 unrelated participants were enrolled at the Women and Children's Hospital of Ningbo University, selected based on clinical manifestations and genetic testing results. The study used next-generation sequencing combined with a homologous sequence alignment (HSA) algorithm, which calculated the sequencing read ratios from homologous regions to identify pathogenic or likely pathogenic variants in the CYP21A2 gene. All detected variants were further validated using long-range PCR or multiplex ligation-dependent probe amplification. The accuracy of the HSA algorithm was systematically assessed. Results: Among the 100 participants, 84 were identified as carriers of CYP21A2 mutations, while 16 were diagnosed with 21-hydroxylase deficiency. A total of 107 pathogenic mutations were detected using the homologous sequence alignment algorithm, comprising of 99 single nucleotide variants or insertions/deletions, 6 copy number variants, and 8 fusion mutations. Additionally, eight cases of CYP21A2-CYP21A1P gene conversions were identified based on HSA scores and confirmed through long-range PCR or multiplex ligation-dependent probe amplification. The algorithm demonstrated a positive predictive value of 96.26% for identifying mutations in CYP21A2. The most frequently observed mutations included c.955C > T, c.844G > T, c.293-13C > G, c.518T > A, and exon-level deletions. Conclusion: In genetic testing, particularly when addressing misalignment challenges associated with highly homologous genes such as CYP21A2, application of the HSA algorithm enables accurate mutation detection using commonly employed short-read sequencing methods. Through the characterization of homologous sequence features and optimization of the HSA algorithm, accurate mutation detection can be achieved in more homologous gene families (eg, HBA1/HBA2, SMN1/SMN2, GBA/GBAP1).

Indexed as

21-hydroxylase deficiencyCYP21A2fusion mutationshighly homologous sequencesHSA algorithmnext generation sequencing

Identifiers

PMID40980470
PMCPMC12449869

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.